Guru Ownership Trend
Guru Analysis for BioCryst Pharmaceuticals, Inc. (BCRX)
BioCryst Pharmaceuticals, Inc. (BCRX), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q2 2026, a total of 9 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $93.49 M.
Top institutional holders include Ken Fisher and Renaissance Technologies (RenTech).
Institutional sentiment is currently Bullish. This is evidenced by a $46.09 M net inflow during the quarter.
Recent activity highlights Cliff Asness who increased their stake by 403.1%. Conversely, Joel Greenblatt reduced exposure by 50.0%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q2 2026)
Guru Consensus (Q2 2026)
FAQs for BioCryst Pharmaceuticals, Inc. (BCRX)
Major holders include Ken Fisher ($26.04 M), Renaissance Technologies (RenTech) ($25.3 M), Cliff Asness ($22.14 M). According to the latest reported data, 9 tracked investment managers collectively hold approximately 9.51 M shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $46.09 M, with 6 managers increasing positions and 3 managers reducing holdings.
During the most recent reporting period, 3 managers trimmed their positions, while 0 fully exited BCRX. The total reported sell value was $4.33 M.
Yes, 4 managers opened new positions in BCRX, and 2 increased their existing holdings. The total reported buy value was $50.42 M.
